Twelve Bio

Main focus: Treatment and diagnostics of genetic diseases

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: CRISPR-Cas12a

Funding stage: Private

Location: Copenhagen, Denmark

Website: https://twelve.bio/

Twelve Bio is a pre-clinical stage gene-editing company that primarily focuses on the Cas12a enzyme. The company is located in Copenhagen, Denmark, as part of the Bioinnovation Institute accelerator, and has yet to disclose its first therapeutic programme.

Twelve Bio

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

Korro Bio to Begin RNA-Editing Trial in Alpha-1...

CMN Clinical

Dec. 4, 2024

Korro Bio has received clearance from the Australian regulatory body to initiate a Phase 1/2 trial of its RNA-editing therapeutic candiate KRRO-110 in...

Sound-Guided CRISPR: Ultrasound Unlocks Precision...

CMN Briefs

Dec. 3, 2024

Scientists engineered ultrasound-controlled CRISPR tools that can precisely edit genes deep within tissues, demonstrating successful gene regulation...

Multimodal Editing Maps Genetic Variants in EGFR

CMN Interview

Dec. 2, 2024

Researchers at ETH Zürich have introduced a combined base and prime editing approach to explore the mutational landscape of the epithelial growth...

CMN Weekly (29 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 29, 2024

Some of the best links we picked up around the internet

CARBON Newsletter (26 November 2024) - Your Latest...

Carbon

Nov. 26, 2024

Some of the best links we picked up around the internet